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Abstract Percutaneous cardioscopy, using high-resolution
fiberoptic imaging, enables direct visualization of the
cardiac interior, thereby enabling macroscopic pathological
diagnosis. Percutaneous cardioscopy has demonstrated that
the endocardial surface exhibits various colors characteris-
tic of different heart diseases. This imaging modality can
now be used for evaluation of the severity of myocardial
ischemia, and staging of myocarditis. Myocardial blood
flow recovery induced by vasodilating agents or percuta-
neous coronary interventions can be clearly visualized.
Morphological and functional changes in the cardiac valves
can also be evaluated. Cardioscope-guided endomyocardial
biopsy enables pin-point biopsy of the diseased myocardi-
um. Recently, dye-image cardioscopy and fluorescence
cardioscopy were developed for evaluation of the subendo-
cardial microcirculation. Cardioscope-guided intracardiac
therapies such as myotomy, myectomy, valvulotomy, and
transendocardial angiogenic and myogenic therapy have
been trialed using animal models in anticipation of future
clinical applications. Percutaneous cardioscopy has the
potential to contribute to our understanding of heart disease,
and to assist in guidance for intracardiac therapies.
Keywords Percutaneous cardioscopy.Dye-staining
cardioscopy.Fluorescence cardioscopy.Cardioscope-
guided endomyocardial biopsy and intracardiac surgery
Introduction
Direct observation of changes in the beating heart was
previously beyond the scope of any available imaging
modalities. Percutaneous cardioscopy, using high-resolution
fiberoptic imaging, enables direct visualization of the cardiac
interior,therebyenablingmacroscopicpathologicaldiagnosis.
This imaging modality is now clinically employed not only
for diagnosis of myocardial and valvular disease, but also for
evaluation of interventional and surgical therapies. In this
article, the past, present, and future prospect of this promising
imaging modality will be presented.
Developmental History of Percutaneous Cardioscopy
Intracardiac observation using a rigid cardioscope in
animals was performed by Allen et al. in 1922 [1] and by
Harken et al. in 1943 [2]. In 1956, Sakakibara et al. [3]
employed a rigid cardioscope to observe a septal defect
during open-heart surgery. They also observed aortic valves
using the same cardioscope in 1958 [4].
Difficulties in producing a thin endoscope that can safely
be introduced percutaneously into the cardiac chambers,
and equipment that can displace blood, meant that about
29 years elapsed before Uchida and his coworkers
successfully performed percutaneous cardioscopy in
patients [5, 6]. Although this new modality of diagnosis is
now performed routinely in a few selected institutions, it
has yet to be adopted on a global scale.
In 1975, a 9-F fiberscope was developed in collaboration
with Olympus Corporation, Tokyo. This cardioscope was
introduced through an 11-F hard-tipped guiding catheter
into a canine left ventricle, but was abandoned due to
marked damage to the endocardial surface. In 1976, a 10-F
balloon-tipped guiding catheter was developed. This cath-
eter allowed the passage of a 6-F fiberscope. However, this
cardioscope also had to be abandoned because the balloon
became frosty during use due to the temperature difference
between the saline used for balloon dilatation and the blood
in the ventricle. In the same year, a fiberscope was devised
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through which warmed saline at body temperature could be
infused to dilate the balloon. The balloon was pushed
against the endocardial surface to observe changes through
the dilated balloon. However, introduction of this fiber-
scope into the left ventricle was very difficult because a
guide wire could not be used, and if used in combination
with a guiding catheter, a big catheter had to be used to
allow the fiberscope to pass through. This fiberscope was
not used clinically. In 1983, a 9-F balloon-guiding catheter
was devised in collaboration with Clinical Supply Company,
Gifu, Japan. When inflated with CO2, the balloon protruded
more distally than the shaft tip to form a dead space between
the target and the balloon, at the same time preventing
damage to the myocardium by the shaft tip. In combination
with a 5-F fiberscope, this balloon catheter enabled
percutaneous transluminal observation of the cardiac cham-
bers and valves (Fig. 1). This cardioscopy system is now
routinely used clinically for observation, not only of the
cardiac chambers and valves, but also of the great vessels
including the pulmonary arteries, caval veins, and aorta.
Cardioscopy System
A cardioscopy system comprises a light source, 4.5-F
fiberscope, 9-F guiding balloon catheter, intensified chilled
coupled device (ICCD) camera, camera controller, DVD
recorder, and television monitor.
The fiberscope (AF 14, Olympus Corporation) is a 4.5-F
fiberscope containing 3,000 glass fibers for image guidance
and 300 glass fibers for light guidance. The fiberscope is
passed through a 9-F guiding balloon catheter (Clinical
Supply Company). The balloon is inflated with CO2. The
catheter has a Y connecter at the proximal end: one channel
for fiberscope insertion and another for saline flushing.
White balance of the cardioscope is adjusted using white
gauze that is immersed in saline solution as the white color
(Fig. 1)[ 7–10].
Cardioscopy Procedures
Left Ventricle
Usually, following coronary angiography and left ventricu-
lography, a guiding balloon catheter is introduced into the
left ventricle and the balloon is inflated with CO2. Next, a
fiberscope is introduced via the guiding catheter to place
the fiberscope tip at the distal most end of the guiding
catheter. The balloon is then gently placed against the
endocardial surface. Since the balloon protrudes 5 mm
ahead of the catheter tip, the distance between the
fiberscope tip and the endocardial luminal surface is
Fig. 1 Cardioscope and
cardioscopy procedure. A,
Cardioscope. a = shaft of
guiding balloon catheter.
b = balloon. c = fiberscope. B,
Observation of the left ventricle
(LV). a = guiding balloon
catheter in this and in c to e.
c = fiberscope in this and in c
to e. C, Observation of tricuspid
valve (TV). d = guidewire
in this and in d and e. D,
Observation of aortic valve
(AoV). E, Observation of mitral
valve (MV). LA, left atrium;
RA, right atrium; RV, right
ventricle
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field is approximately 1.2 cm in saline. Heparinized saline
solution (10 IU/mL) is then infused at a rate of 10 mL/s
using a power injector for 5 s to displace the blood between
the endocardial surface and the fiberscope. The guiding
balloon catheter is pre-shaped to easily locate on the
targeted wall segment; an “S” or “crank” configuration for
the anterior, apical, and inferior wall segments; a “J”
configuration for lateral wall segment; and an “L” config-
uration for the high posterior wall segment (Fig. 1B)[ 10].
Right Ventricle
Observation of the right ventricle is essentially the same as
for the left ventricle. Use of a guiding balloon catheter “J”
or “U” configuration is recommended.
Right Atrium
The free wall of the right atrium and the atrial septum can
be observed using a “J” configuration guiding balloon
catheter.
Left Atrium
The guiding balloon catheter must be introduced trans-
septally from the right atrium into the left atrium for
observation of the left atrial wall.
Cardiac Valves
For observation of the aortic, mitral, and tricuspid and
pulmonary valves, it is necessary to use a guidewire to
anchor the catheter tip for observation, as shown schemat-
ically in Fig. 1C to E [7, 10].
Measurement of Lesion Sizes
Measurement of lesion sizes is beyond the scope of present
cardioscopy systems because it uses a fish-eye lens.
Nevertheless, lesion sizes can be roughly assessed using
the diameter of a guidewire tip that is placed on or adjacent
to the lesion.
Cardioscope-Guided Endomyocardial Biopsy System
A cardioscope-guided biopsy system has also been devised
to safely guide endomyocardial biopsy and to confirm
changes in the biopsied portion. A 1.6-F fiberscope is
attached to a bioptome. This system is introduced through
either a 9-F guiding balloon catheter or a 9-F soft-tipped
catheter into a cardiac chamber, and a biopsy is taken while
observing the area to be biopsied [7, 12].
Combination of Cardioscopy and Intracardiac
Ultrasound
The cardiac chambers and valves are usually observed by
cardioscopy in combination with intracardiac ultrasound
(ICUS). An ICUS probe is introduced through the right
femoral artery into the left ventricle, guided by a 0.035-inch
guide wire. The guide wire is advanced to the apex first,
and then the probe is advanced to the apex. Use of a
radiofocus guide wire (Terumo Company, Tokyo) is
recommended because it is very steerable. Pulling back
the probe slowly, pineapple-like slices of the left ventricle
from the apex to the aortic valve can be successively
obtained. A 15-MHz probe is usually used for a normal-
sized left ventricle. When the ventricle is large, a 12-MHz
probe is used to cover the entire chamber.
For right heart examinations, an ICUS probe is intro-
duced through the right femoral vein into the pulmonary
artery, guided by a 0.035-inch guide wire. The probe is
slowly pulled back toward the right atrium. By this
maneuver, pineapple-like slices of the right ventricle can
be successively obtained. Details of this procedure are
described elsewhere [10, 13].
Observation of the Cardiac Chambers
Coronary Artery Disease
Endocardial color has been reported to indicate the severity of
myocardial ischemia and fibrosis. The endocardial surface is
brown in patients without heart disease when observed by
flushing saline solution. The endocardial color of the left
ventricular wall in patients with coronary artery disease is
classified as brown, light brown, pale (bluish white closely
resembling the endocardial color of the Langendorff heart in
which the blood is replaced by an artificial solution [14]), and
white (Fig. 2). Regional left ventricular contraction assessed
using ICUS is usually normokinetic, normokinetic, hypo-to-
akinetic, and akinetic-to-dyskinetic, respectively (Fig. 2).
These endocardial colors, however, do not correlate signif-
icantly with the severity of stenosis of the irrigating
epicardial artery or collateral development, suggesting that
the regional microcirculation is the determinant of regional
blood flow and accordingly endocardial color [7]. White
trabecular edges are characteristic of vasospastic angina.
Transient but severe ischemia due to coronary spasm may
cause fibrosis of the trabecular edges that are most
susceptible to ischemia [7].
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Endomyocardial biopsy is essential to make a definite
diagnosis of myocarditis. However, when fluoroscopy is
used to guide endomyocardial biopsy, chance decides
whether or not the diseased myocardium is biopsied,
possibly leading to misdiagnosis. If endocardial surface
changes are indicative of the stage of myocarditis, staging
of myocarditis can be performed by percutaneous cardio-
scopy, enabling observation of the cardiac chambers from
within, and targeted cardioscope-guided biopsy can be
performed for accurate histological diagnosis.
Cardioscope-guided endomyocardial biopsy was per-
formed in 59 patients with idiopathic myocarditis. Left
ventricular endocardial color and histological changes
were compared. Cardioscopic follow-up studies were
performed for 6 months. In contrast to the brown color
seen in patients with normal histology, the endocardial
surface was red, milky white, purple, white, or yellowish
brown in patients with idiopathic myocarditis. Biopsy
specimens obtained from red and milky white segments
exhibited histological changes indicative of acute myo-
carditis, purple segments of active chronic myocarditis,
and yellowish brown and white segments of inactive
chronic myocarditis (Fig. 3)[ 13, 15, 16].
Cardioscopic follow-up studies revealed that red and
milky white surface was changed to purple or white, and
purple surface was often changed to white or yellowish
brown, indicating transformation of inflammatory stages.
Thus, left ventricular endocardial colors that were observed
by cardioscopy represented histological stages of idiopathic
myocarditis. This imaging tool is therefore considered to be
feasible for staging and follow-up of idiopathic myocarditis
[13, 15, 16].
Fig. 2 Left ventricular endocardial color in patients with coronary
artery disease. From A to D, Brown, light brown, pale, and white.
Arrow in d = atrophic trabeculae. a to d, Corresponding intracardiac
ultrasound images at diastole. α to δ, Corresponding intracardiac
ultrasound images at systole. From α to δ, Normokinetic, normoki-
netic, hypokinetic anterior wall (arrow), and akinetic inferior wall
(arrow), respectively. Arrows in a to c and α to γ, anterior wall.
Arrows in d and δ, inferior wall
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In general, the left ventricular endocardial color is white or
yellowish brown and trabeculae are thin and atrophic in
patients with dilated cardiomyopathy. Since the endocardial
color resembles that of inactive idiopathic myocarditis,
histological examination is essential to make a definitive
diagnosis [17].
Idiopathic Hypertrophic Cardiomyopathy
The most outstanding change in the left ventricle in patients
with hypertrophic cardiomyopathy is the presence of thick
trabeculae. These are usually light brown at first, later
turning white due to fibrosis in the dilated phase [18].
Subendocardial Microvessels
The coronary microvessels play a direct and critical role in
determining the extent and severity of myocardial ischemia
and symptoms, and preservation of cardiac function.
Participation of microvessel dysfunction is suspected, but
not confirmed, in the slow-flow or no-flow phenomenon
associated with percutaneous coronary intervention [19],
Takotsubo cardiomyopathy [20], peripartum cardiomyopa-
thy [21], syndrome X [22], and microvessel angina [23].
Direct visualization may help to elucidate the mecha-
nisms of these heart diseases. However, there are no
clinically available methods for direct imaging of coronary
microvessels in vivo.
The subendocardial microvessels were observed using
cardioscopy in patients with coronary artery disease. It was
revealed that subendocardial arterial and venous microvessels
located in normokinetic-to-hypokinetic left ventricular wall
segments were filled with the blood during diastole and
collapsed during systole. In contrast, subendocardial arterial
and venous microvessels located in akinetic-to-dyskinetic wall
segments were filled with the blood during systole and
collapsed during diastole. No significant correlation was found
between these changes and the severity of stenosis of the
irrigating epicardial coronary arteries or collateral develop-
ment. These findings suggest that the contractile state of the
myocardiumisthemaindeterminantofthetimingofperfusion
of the subendocardial microvessels in patients with coronary
artery disease [24].
Left Ventricular Thrombus
It is well known that a fibrillating left atrium is a site of
thrombus formation, acting as a major supply source of
thromboemboli in cerebral ischemic attacks [25–28]. It is
also known that the left ventricle is a site of thrombus
f o r m a t i o ni nt h ep o s t -infarction state [29]. Other heart
diseases such as peripartal cardiomyopathy [30], idio-
pathic dilated cardiomyopathy [31], acute myocarditis
[32], and antiphospholipid syndrome [33] may cause
cerebral embolism [34, 35]. However, the exact incidence
of left ventricular thrombus (LVT) in various categories
of heart disease is unclear due to the lack of systematic
surveys.
Fig. 3 Left ventricular endocar-
dial color in patients with
idiopathic myocarditis. A,
Normal control. Arrow indicates
trabeculae. B to F, Red indicat-
ing acute myocarditis, milky
white indicating acute myocar-
ditis, purple indicating active
chronic myocarditis, white indi-
cating inactive chronic myocar-
ditis, and yellowish brown
indicating inactive chronic
myocarditis
as determined by biopsy,
respectively
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26% of 258 patients with heart diseases. Cardioscopically,
LVT are classified by shape as globular (protruding) and
mural (lined), and by color as red, white, and yellow
(Fig. 4). The majority of LVTs detected were mural. LVT
was detected in 12.5% of patients with stable angina, 0%
with unstable angina, 45.2% with acute myocardial infarc-
tion, 23.5% with old myocardial infarction, 61.9% with
idiopathic acute myocarditis, 44.3% with idiopathic chronic
myocarditis, 33.3% with rheumatic valvular disease, 25.7%
with idiopathic dilated cardiomyopathy, and 8.0% with
idiopathic hypertrophic cardiomyopathy. The LVT detec-
tion rates using cardioscopy, left ventriculography, non-
contrast echocardiography, and contrast echocardiography
were 30.2%, 2.7%, 1.9%, and 7.0%, respectively [36, 37].
Thus, LVT is common in patients with various heart
diseases, especially acute myocardial infarction and acute
myocarditis, and although invasive, cardioscopy is more
sensitive in detecting LVT than left ventriculography or
non-contrast and contrast echocardiography.
Observation of Cardiac Valves
Direct observation of the cardiac valves in the beating heart
was previously beyond the scope of any available imaging
modalities. Figure 5 shows the morphology and motion of
normal aortic and mitral valves. Figure 6 shows the surface
morphology of diseased aortic cusp and mitral leaflets as
visualized using cardioscopy [38, 39].
Cardioscopy and intracardiac ultrasound allow us to
observe not only morphological changes, but also to
examine precisely the motion of the cardiac valves.
Evaluation of Medical, Interventional, and Surgical
Therapies
Effects of Nitroglycerine
The subendocardial myocardial layer is most susceptible to
ischemia. To improve blood flow in this layer is therefore an
essential requisite for the treatment of coronary artery disease.
Nitroglycerine (NTG) is a well-known antianginal agent. The
question of whether NTG increases blood flow to the
subendocardial myocardial layer is controversial, however.
Changes in subendocardial myocardial blood flow
(SMBF) induced by the intravenous administration of
200 μg of NTG were examined using cardioscopy in
patients with coronary artery disease.
Figure 7 shows an example of NTG-induced recovery of
myocardial blood flow in a patient with angina pectoris. On
administration of NTG, the endocardial color changed to red
in brown and light brown segments, indicating arterial blood
filling. Variable changes were seen in pale segments: turned
purple, indicating venous blood filling; turned red, indicating
arterial blood filling, or showed no change. No changes were
seen in the white segments, indicating no blood filling.
NTG-induced changes in endocardial color were therefore
closely related to the control color. Although there was a
tendency for arterial blood filling to occur in segments
irrigated by a less stenotic artery, with developed collaterals
and with well preserved contraction, the difference was not
statistically significant [40, 41]. It is conceivable that
regional microvessels, and not large epicardial coronary
arteries, directly mediate the effects of NTG on SMBF.
Evaluation of Percutaneous Coronary Interventions
The effects of percutaneous coronary interventions were
examined using cardioscopy in patients with acute coronary
syndrome. Pale endocardial color often turned dark red
indicating reperfusion hyperemia.
Evaluation of Percutaneous Transseptal Mitral
Commissurotomy
Figure 8 shows the posterior commissure of the mitral valve
in a patient with rheumatic mitral stenosis. The fused
commissure was separated using percutaneous transseptal
Fig. 4 Color of left ventricular thrombi (LVT). A, Red LVT (arrow)
in a 66-year-old man with old myocardial infarction (OMI). B, White
LVT (arrow) in a 47-year-old woman with chronic myocarditis. C,
Yellow LVT (arrow) in a 50-year-old man with OMI. D, Red-and-
yellow in a mosaic pattern LVT in a 71-year-old man with OMI.
Arrow indicates yellow LVT. Arrowhead indicates red LVT
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evaluation of catheter-based commissurotomy not only of
the mitral valve, but also other cardiac valves.
Evaluation of Cardiac Surgery
Cardioscopy can be used for evaluation of surgery of
congenital heart diseases such as atrial septal defect,
anomalous pulmonary vein drainage, and aortic disease.
Fig. 6 Diseased aortic and mitral valves. A and B, Yellow and thick
noncoronary cusp in a patient with rheumatic aortic regurgitation
during systole and diastole, respectively (arrows). C and D, Yellow
and thick posterior mitral leaflet (arrowhead) and anterior leaflet
(arrows) during systole and diastole in a patient with rheumatic mitral
steno-regurgitation, respectively. (From Uchida [10]; with permission)
Fig. 5 Cardioscopic images of normal aortic and mitral valves. A to C, Process of aortic valve closing. Arrows indicate noncoronary cusp. D to F,
Process of mitral valve opening of normal mitral valve. Arrows indicate anterior leaflet
Fig. 7 Effects of nitroglycerin (NTG) on subendocardial myocardial
blood flow. A and B, Before and 3 min after the intravenous injection
of 200 μg NTG, respectively. The endocardial color changed from
white to red, indicating increased blood flow (arrow in B). (From
Uchida [7]; with permission)
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of the risk of valvular damage [10].
New Cardioscopic Modalities
Dye-Staining Cardioscopy
Dye-stainingcardioscopy,usinga dye asanindicator ofblood
flow, is useful for the identification of regional myocardial
blood flow. During observation of a wall segment, a selective
bolus injection of 1 mL of 2% Evans blue solution into the
irrigating coronary artery results in staining of the wall
segment when the artery is patent, but no or partial staining
when the artery is obstructed or stenosed. Figure 9B shows
diffuse staining of the myocardium following selective
intracoronary injection of Evans blue dye in a patient with
chest pain syndrome, indicating normal preservation of
myocardial blood flow. Figure 9D shows patchy staining of
the myocardium in a patient with old myocardial infarction,
indicating regional disturbance of myocardial blood flow.
Dye-staining cardioscopy was performed before and
after coronary stent implantation in patients with acute
myocardial infarction. This showed that despite successful
recanalization of the obstructed epicardial coronary artery,
the endocardial surface was not necessarily stained with
Evans blue, indicating that coronary microcirculation was
not necessarily restored by apparently successful epicardial
coronary recanalization [42￿].
Fluorescence Cardioscopy
Fluorescein generates fluorescence at 520 nm when excited
by 470 nm light, and is routinely used for detection of
Fig. 9 Dye-staining cardioscopy. A and B, Left ventricular endocar-
dial color before and after intracoronary injection of Evans blue dye in
a subject without coronary artery disease. Note diffuse staining,
indicating normal blood flow (arrow in B). C and D, Left ventricular
endocardial color before and after intracoronary injection of Evans
blue dye in a patient with old myocardial infarction. Note patchy
staining (arrow in D). (From Uchida et al. [42￿]; with permission)
Fig. 8 Evaluation of percutaneous transseptal mitral commissurotomy
(PTMC) in a 44-year-old woman with rheumatic mitral stenosis. A
Fusion of the posterior commissure (arrow). B, Separation of the
fused commissure by PTMC (arrow). (From Uchida [10]; with
permission)
Fig. 10 Fluorescence cardioscopy. A, Left ventriculograms in a
patient with chest pain syndrome. The apical segment shows diffuse
fluorescence after intravenous injection of fluorescein B, indicating
normal myocardial tissue fluid flow. C, Left ventriculograms in a
patient with old myocardial infarction. The apical segment shows
patchy fluorescence, indicating regional disturbance of fluid flow D.
(From Uchida et al. [43￿￿]; with permission)
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mellitus. When injected into a vessel, its fluorescence is
masked by blood cells, but after diffusion through the
vascular wall into the tissues, it exhibits fluorescence.
Therefore, the presence of fluorescence in a tissue indicates
existence of tissue fluid flow and accordingly blood flow in
the irrigating vessel.
Figure 10B shows diffuse staining of the left ventric-
ular endocardial surface by the intravenous injection of
fluorescein in a patient with chest pain syndrome,
indicating preserved myocardial tissue fluid flow.
Figure 10D shows patchy staining of the myocardium in
a patient with old myocardial infarction, indicating tissue
flow disturbance and accordingly regional blood flow
disturbance [43￿￿].
After successful percutaneous coronary interventions,
fluorescence appears or its intensity is increased, indicating
restoration of tissue fluid flow (Fig. 11). However,
myocardial tissue flow does not necessarily normalize,
indicating that successful epicardial coronary recanalization
does not necessarily result in recovery of coronary
microcirculation.
These results obtained using dye-staining and fluores-
cence cardioscopy suggest a need for new modalities for
treatment of coronary microcirculatory disturbances.
Future Directions for Cardioscopy
Cardioscope-Guided Intracardiac Surgery
Cardioscope-guided myotomy, myectomy, and valvulot-
omy have been trialed in animals in anticipation of their
clinical application [44–47]. These therapeutic modali-
ties will soon be available for application in clinical
situations.
Cardioscope-Guided Trans-endocardial Angiogenic
and Myogenic Therapy
About 15% of patients with ischemic heart disease are
not indicated for surgical or other interventions. At
present, no other curative treatments are available for
them.
Myocardial salvage through the formation of new blood
vessels by either angiogenesis or vasculogenesis (angio-
genic therapy) is one promising therapeutic modality for
these patients. Cardioscope-guided trans-endocardial angio-
genic therapy has been trialed in animals [48]. Using dye-
staining and fluorescence cardioscopy, pin-point angiogenic
and myogenic therapy can be performed with more
precision in the clinical situation.
Fig. 11 Fluorescence cardioscopy before and after percutaneous
coronary intervention (PCI). A and E, Conventional cardioscopy
before and after PCI, respectively. The endocardial color changed
from white to red, indicating restoration of blood flow. B to D, Time-
course changes in fluorescence intensity before PCI. F to H, Time-
course changes in fluorescence intensity after PCI. An increase in
fluorescence intensity indicates flow restoration is evident. (From
Uchida et al. [43￿￿]; with permission)
Curr Cardiovasc Imaging Rep (2011) 4:317–327 325Conclusions
Recent advances in cardioscopy technology enable us to
observe the interior of the heart. This imaging technology is
now used for the diagnosis of myocardial and valvular
diseases, evaluation of the severity of myocardial ischemia,
interventional and surgical treatments, and for guidance of
endomyocardial biopsy. This technique will be employed
for the guidance of transcatheter interventional and surgical
treatments of various heart diseases in the near future.
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